Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy
Hand-out
Press Releases
Qnovia, Inc.  
December 10, 2024

Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy

- Company has raised $50 million since its inception -

avatar profile Olean Times Herald

Olean Times Herald


Local & Social